Lymphocytes as an Indicator for Initial Kidney Function: A Single Center Analysis of Outcome after Alemtuzumab or Basiliximab Induction

@inproceedings{Weissenbacher2015LymphocytesAA,
  title={Lymphocytes as an Indicator for Initial Kidney Function: A Single Center Analysis of Outcome after Alemtuzumab or Basiliximab Induction},
  author={Annemarie Weissenbacher and Theresa Hautz and Michael Kimelman and Rupert Oberhuber and Hanno Ulmer and Claudia B{\"o}sm{\"u}ller and M Maglione and Stefan Schneeberger},
  booktitle={Journal of immunology research},
  year={2015}
}
Alemtuzumab, an anti-CD52 T-cell and B-cell depleting monoclonal antibody, is established for induction therapy in renal transplantation (KTx). We herein provide a comparative analysis between alemtuzumab and basiliximab induction therapy and correlate lymphocyte depletion and recovery with the clinical course after KTx. This is a single center retrospective analysis of 225 patients/consecutive kidney transplantations treated with alemtuzumab for lymphocyte depletion and 205 recipients treated… CONTINUE READING

References

Publications referenced by this paper.
SHOWING 1-10 OF 51 REFERENCES

An analysis of lymphocyte phenotype after steroid avoidancewith either alemtuzumab or basiliximab induction in renal transplantation

A. D. Salama, C. Carter
  • American Journal of Transplantation
  • 2012

C

A. Cherukuri, A. D. Salama
  • Carter et al., “An analysis of lymphocyte phenotype after steroid avoidancewith either alemtuzumab or basiliximab induction in renal transplantation,” American Journal of Transplantation, vol. 12, no. 4, pp. 919–931
  • 2012

E

C. Macedo, J. T. Walters
  • A. Orkis et al., “Long-term effects of alemtuzumab on regulatory and memory T-cell subsets in kidney transplantation,” Transplantation, vol. 93, no. 8, pp. 813– 821
  • 2012
VIEW 1 EXCERPT

J

R. D. Morgan
  • M. O’Callaghan, S. R. Knight, and P. J. Morris, “Alemtuzumab induction therapy in kidney transplantation: a systematic review and meta-analysis,” Transplantation, vol. 93, no. 12, pp. 1179–1188
  • 2012
VIEW 2 EXCERPTS

Alemtuzumab: right drug, right dose?

  • Transplant international : official journal of the European Society for Organ Transplantation
  • 2011
VIEW 1 EXCERPT

C

K. Chan, D. Taube
  • Roufosse et al., “Kidney transplantation with minimized maintenance: alemtuzumab induction with tacrolimus monotherapy-an open label, randomized trial,” Transplantation, vol. 92, no. 7, pp. 774–780
  • 2011
VIEW 1 EXCERPT

Clinical assessment and determinants of chronic allograft nephropathy in maintenance renal transplant patients.

  • Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association
  • 2011

G

J. Sageshima, G. Ciancio
  • Guerra et al., “Prolonged lymphocyte depletion by single-dose rabbit anti-thymocyte globulin and alemtuzumab in kidney transplantation,” Transplant Immunology, vol. 25, no. 2-3, pp. 104–111
  • 2011
VIEW 1 EXCERPT